{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:15:19Z","timestamp":1788322519362,"version":"build-2803163510"},"reference-count":98,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"am","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R56 AR054447"],"award-info":[{"award-number":["R56 AR054447"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["RO1 AR077152"],"award-info":[{"award-number":["RO1 AR077152"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA013696"],"award-info":[{"award-number":["P30CA013696"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100162"],"award-info":[{"award-number":["82100162"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006474","name":"Columbia University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006474","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","award":["R35 CA253126"],"award-info":[{"award-number":["R35 CA253126"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ccell.2025.03.007","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T12:17:32Z","timestamp":1743250652000},"page":"1007-1024.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies"],"prefix":"10.1016","volume":"43","author":[{"given":"Ioanna","family":"Mosialou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Labella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brygida","family":"Bisikirska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Cuesta-Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi","family":"Vgenopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismarc","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana M.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Galan-Diez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Chernak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Philipp","family":"Bewersdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Fukasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Higa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Corper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Pampou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Feldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00ebl","family":"Heiblig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kornblau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellin","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Jurcic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Rabadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Kousteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2025.03.007_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ccell.2025.03.007_bib2","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1200\/JCO.2014.55.1564","article-title":"Acute myeloid leukemia and myelodysplastic syndromes in older adults","volume":"32","author":"Klepin","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.03.007_bib3","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3324\/haematol.2020.248955","article-title":"Myelodysplastic syndromes: moving towards personalized management","volume":"105","author":"Hellstr\u00f6m-Lindberg","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ccell.2025.03.007_bib4","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2025.03.007_bib5","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2025.03.007_bib6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2025.03.007_bib7","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2025.03.007_bib8","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis","volume":"44","author":"Busque","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccell.2025.03.007_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004315","article-title":"Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia","volume":"4","author":"Jan","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ccell.2025.03.007_bib10","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2025.03.007_bib11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nature12883","article-title":"Leukaemogenesis induced by an activating \u03b2-catenin mutation in osteoblasts","volume":"506","author":"Kode","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2025.03.007_bib12","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nature08851","article-title":"Bone progenitor dysfunction induces myelodysplasia and secondary leukemia","volume":"464","author":"Raaijmakers","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2025.03.007_bib13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.stem.2016.08.021","article-title":"Mesenchymal Inflammation Drives Genotoxic Stress in Hematopoietic Stem Cells and Predicts Disease Evolution in Human Pre-leukemia","volume":"19","author":"Zambetti","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ccell.2025.03.007_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ccell.2025.03.007_bib15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.stem.2015.02.014","article-title":"Normal and leukemic stem cell niches: insights and therapeutic opportunities","volume":"16","author":"Schepers","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ccell.2025.03.007_bib16","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.cell.2007.05.014","article-title":"A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency","volume":"129","author":"Walkley","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2025.03.007_bib17","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nature20131","article-title":"Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment","volume":"539","author":"Dong","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2025.03.007_bib18","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1182\/blood-2016-08-736454","article-title":"Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apcdel\/+ MDS mouse model","volume":"129","author":"Stoddart","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2025.03.007_bib19","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2009-11-251728","article-title":"The Apcmin mouse has altered hematopoietic stem cell function and provides a model for MPD\/MDS","volume":"115","author":"Lane","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2025.03.007_bib20","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1158\/0008-5472.CAN-17-0282","article-title":"Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt\/beta-Catenin Activation","volume":"77","author":"Bhagat","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2025.03.007_bib21","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ccell.2025.03.007_bib22","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood.V93.8.2478","article-title":"Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +\/- all-trans retinoic acid +\/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome","volume":"93","author":"Estey","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2025.03.007_bib23","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00277-016-2810-z","article-title":"All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study","volume":"95","author":"Schlenk","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ccell.2025.03.007_bib24","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2005-10-4202","article-title":"Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial","volume":"107","author":"Milligan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2025.03.007_bib25","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/sj.leu.2403528","article-title":"Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia","volume":"18","author":"Schlenk","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2025.03.007_bib26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.yexcr.2016.12.007","article-title":"Retinoic acid receptor signalling directly regulates osteoblast and adipocyte differentiation from mesenchymal progenitor cells","volume":"350","author":"Green","year":"2017","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ccell.2025.03.007_bib27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.19.01053","article-title":"Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 \u00d7 2, Phase II Trial","volume":"38","author":"L\u00fcbbert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.03.007_bib28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3324\/haematol.2011.048231","article-title":"A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy","volume":"97","author":"L\u00fcbbert","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.ccell.2025.03.007_bib29","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","article-title":"Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome","volume":"110","author":"Soriano","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2025.03.007_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41408-022-00715-4","article-title":"The antileukemic activity of decitabine upon PML\/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation","volume":"12","author":"Meier","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ccell.2025.03.007_bib31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12885-015-1432-5","volume":"15","author":"Grishina","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ccell.2025.03.007_bib32","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41375-020-0892-z","article-title":"A proof of concept phase I\/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory\/relapsed AML patients not eligible for intensive therapy","volume":"35","author":"Wass","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2025.03.007_bib33","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1158\/1078-0432.CCR-20-4054","article-title":"Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies","volume":"27","author":"Tayari","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2025.03.007_bib34","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1186\/s12885-017-3620-y","article-title":"Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells","volume":"17","author":"Reikvam","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ccell.2025.03.007_bib35","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood.2020010100","article-title":"Retinoids in hematology: a timely revival?","volume":"137","author":"Geoffroy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2025.03.007_bib36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/sj.thj.6200141","article-title":"All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial","volume":"3","author":"Belhabri","year":"2002","journal-title":"Hematol. J."},{"key":"10.1016\/j.ccell.2025.03.007_bib37","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.2009.22.9088","article-title":"Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial","volume":"28","author":"Burnett","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.03.007_bib38","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/sj.onc.1204763","article-title":"All trans retinoic acid in acute promyelocytic leukemia","volume":"20","author":"Degos","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.ccell.2025.03.007_bib39","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ccell.2017.10.002","article-title":"Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure","volume":"32","author":"de Th\u00e9","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2025.03.007_bib40","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrc2943","article-title":"Acute promyelocytic leukaemia: novel insights into the mechanisms of cure","volume":"10","author":"de Th\u00e9","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccell.2025.03.007_bib41","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/annonc\/mdw171","article-title":"Current management of newly diagnosed acute promyelocytic leukemia","volume":"27","author":"Cicconi","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2025.03.007_bib42","first-page":"CD011960","article-title":"Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL))","volume":"8","author":"K\u00fcley-Bagheri","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ccell.2025.03.007_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-41964-y","article-title":"Randomized phase-III study of low-dose cytarabine and etoposide +\/- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia","volume":"13","author":"Schlenk","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ccell.2025.03.007_bib44","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/bloodadvances.2022008806","article-title":"Targeting RARA overexpression with tamibarotene, a potent and selective RAR\u03b1 agonist, is a novel approach in AML","volume":"7","author":"de Botton","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ccell.2025.03.007_bib45","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/nm.1891","article-title":"Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation","volume":"14","author":"Nasr","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2025.03.007_bib46","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0092-8674(91)90112-C","article-title":"Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML","volume":"66","author":"Kakizuka","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2025.03.007_bib47","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0092-8674(91)90113-D","article-title":"The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR","volume":"66","author":"de Th\u00e9","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2025.03.007_bib48","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0960-9822(00)80088-3","article-title":"Cross-regulation of beta-catenin-LEF\/TCF and retinoid signaling pathways","volume":"9","author":"Easwaran","year":"1999","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ccell.2025.03.007_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143255","article-title":"All-Trans Retinoic Acid-Induced Deficiency of the Wnt\/\u03b2-Catenin Pathway Enhances Hepatic Carcinoma Stem Cell Differentiation","volume":"10","author":"Zhu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ccell.2025.03.007_bib50","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1097-2765(01)00241-6","article-title":"Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein","volume":"7","author":"Liu","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ccell.2025.03.007_bib51","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.1038\/ncomms7156","article-title":"Tumour suppressor TRIM33 targets nuclear \u03b2-catenin degradation","volume":"6","author":"Xue","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2025.03.007_bib52","doi-asserted-by":"crossref","first-page":"23505","DOI":"10.1074\/jbc.M113.473801","article-title":"c-Cbl, a ubiquitin E3 ligase that targets active \u03b2-catenin: a novel layer of Wnt signaling regulation","volume":"288","author":"Chitalia","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ccell.2025.03.007_bib53","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/2159-8290.CD-17-0399","article-title":"Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RAR\u03b1 Dependency Targetable by SY-1425, a Potent and Selective RAR\u03b1 Agonist","volume":"7","author":"McKeown","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2025.03.007_bib54","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation","volume":"8","author":"Glass","year":"2005","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ccell.2025.03.007_bib55","doi-asserted-by":"crossref","first-page":"E407","DOI":"10.1073\/pnas.1221385110","article-title":"STOP gene Phactr4 is a tumor suppressor","volume":"110","author":"Solimini","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2025.03.007_bib56","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.thj.6200132","article-title":"A case of pancreatitis associated with all-trans-retinoic acid therapy in acute promyelocytic leukemia","volume":"2","author":"Abou Chacra","year":"2001","journal-title":"Hematol. J."},{"key":"10.1016\/j.ccell.2025.03.007_bib57","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/jjco\/hyi027","article-title":"Acute pancreatitis during all-trans-retinoic acid treatment for acute promyelocytic leukemia in a patient without overt hypertriglyceridemia","volume":"35","author":"Teng","year":"2005","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.03.007_bib58","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4103\/ijmpo.ijmpo_36_16","article-title":"Pancreatitis in Acute Promyelocytic Leukemia: Drug-induced or Differentiation Syndrome?","volume":"38","author":"De","year":"2017","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"10.1016\/j.ccell.2025.03.007_bib59","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12185-008-0116-1","article-title":"All-trans-retinoic acid as a possible cause of acute pancreatitis even in the absence of hypertriglyceridemia","volume":"88","author":"Hoshino","year":"2008","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.ccell.2025.03.007_bib60","first-page":"1008","article-title":"Endogenous and combination retinoids are active in myelomonocytic leukemias","volume":"106","author":"Di Martino","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ccell.2025.03.007_bib61","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1101\/gad.1771409","article-title":"Mouse models of human AML accurately predict chemotherapy response","volume":"23","author":"Zuber","year":"2009","journal-title":"Genes Dev."},{"key":"10.1016\/j.ccell.2025.03.007_bib62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.ccell.2025.03.007_bib63","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/bloodadvances.2020003841","article-title":"5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice","volume":"5","author":"Bankova","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.ccell.2025.03.007_bib64","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2025.03.007_bib65","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2025.03.007_bib66","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.celrep.2016.03.066","article-title":"RUNX2 Mediates Plasmacytoid Dendritic Cell Egress from the Bone Marrow and Controls Viral Immunity","volume":"15","author":"Chopin","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ccell.2025.03.007_bib67","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1146\/annurev.genom.9.081307.164437","article-title":"Transcriptional control of skeletogenesis","volume":"9","author":"Karsenty","year":"2008","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.ccell.2025.03.007_bib68","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/stem.3174","article-title":"CXCR4 expression in the bone marrow microenvironment is required for hematopoietic stem and progenitor cell maintenance and early hematopoietic regeneration after myeloablation","volume":"38","author":"Singh","year":"2020","journal-title":"Stem Cell."},{"key":"10.1016\/j.ccell.2025.03.007_bib69","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1096\/fj.12-225763","article-title":"CXCL12\/CXCR4 signaling in the osteoblast regulates the mesenchymal stem cell and osteoclast lineage populations","volume":"27","author":"Shahnazari","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.ccell.2025.03.007_bib70","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa044264","article-title":"Circulating osteoblast-lineage cells in humans","volume":"352","author":"Eghbali-Fatourechi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2025.03.007_bib71","first-page":"663","article-title":"Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre","volume":"144","author":"Zhou","year":"2024","journal-title":"Randomized Controlled Trial"},{"key":"10.1016\/j.ccell.2025.03.007_bib72","first-page":"6545","article-title":"A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia","volume":"42","author":"Gu","year":"2024","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.ccell.2025.03.007_bib73","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/ejh.14304","article-title":"Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine","volume":"114","author":"Bresser","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ccell.2025.03.007_bib74","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2025.03.007_bib75","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2025.03.007_bib76","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2025.03.007_bib77","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2001.19.5.1405","article-title":"Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis","volume":"19","author":"Christiansen","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.03.007_bib78","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1182\/blood-2019-127038","article-title":"Deletions of 5q Promote Genome Instability in TP53-Mutant MDS\/AML","volume":"134","author":"Reilly","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2025.03.007_bib79","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/gcc.22151","article-title":"Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome","volume":"53","author":"Volkert","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ccell.2025.03.007_bib80","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1002\/cam4.5421","article-title":"Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency","volume":"12","author":"Zhao","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.ccell.2025.03.007_bib81","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41408-021-00416-4","article-title":"Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis","volume":"11","author":"Pitel","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ccell.2025.03.007_bib82","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"Rucker","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2025.03.007_bib83","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/bjh.16151","article-title":"Differentiation syndrome in acute promyelocytic leukaemia","volume":"187","author":"Stahl","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ccell.2025.03.007_bib84","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7326\/0003-4819-117-4-292","article-title":"The \u201cretinoic acid syndrome\u201d in acute promyelocytic leukemia","volume":"117","author":"Frankel","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ccell.2025.03.007_bib85","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2025.03.007_bib86","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154515","article-title":"\u03b2-Catenin signaling in hepatocellular carcinoma","volume":"132","author":"Xu","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ccell.2025.03.007_bib87","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.3390\/cells9092125","article-title":"Transcriptional Regulation of Wnt\/\u03b2-Catenin Pathway in Colorectal Cancer","volume":"9","author":"Bian","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ccell.2025.03.007_bib88","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12943-020-01276-5","article-title":"Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities","volume":"19","author":"Xu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ccell.2025.03.007_bib89","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1038\/s41467-020-18636-w","article-title":"Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer","volume":"11","author":"Kocher","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2025.03.007_bib90","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1186\/s12885-017-3620-y","article-title":"Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia \u2013 identification of responders by gene expression profiling of pretreatment leukemic cells","volume":"17","author":"Reikvam","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ccell.2025.03.007_bib91","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ccell.2025.03.007_bib92","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ccell.2025.03.007_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/leu.2015.161","article-title":"FoxO1-dependent induction of acute myeloid leukemia by osteoblasts in mice","volume":"30","author":"Kode","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2025.03.007_bib94","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cmet.2010.01.001","article-title":"FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts","volume":"11","author":"Rached","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.ccell.2025.03.007_bib95","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/nm.4103","article-title":"A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells","volume":"22","author":"Reinisch","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2025.03.007_bib96","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0960-9822(03)00240-9","article-title":"Zebrafish prickle, a modulator of noncanonical Wnt\/Fz signaling, regulates gastrulation movements","volume":"13","author":"Veeman","year":"2003","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ccell.2025.03.007_bib97","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2025.03.007_bib98","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610825001084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610825001084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T11:01:34Z","timestamp":1749466894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610825001084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1535610825001084"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2025.03.007","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2025.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}